Format

Send to

Choose Destination
Am J Emerg Med. 2014 Dec;32(12):1503-9. doi: 10.1016/j.ajem.2014.09.023. Epub 2014 Sep 28.

Tranexamic acid for traumatic brain injury: a systematic review and meta-analysis.

Author information

1
Department of Emergency Medicine, State University of New York, Downstate Medical Center, Brooklyn, NY. Electronic address: Shahriar.zehtabchi@downstate.edu.
2
Department of Emergency Medicine, State University of New York, Downstate Medical Center, Brooklyn, NY. Electronic address: samahabdulbaki@gmail.com.
3
Center for Behavioral Cardiovascular Health, Department of Medicine, Columbia University Medical Center, New York, NY. Electronic address: af2215@cumc.columbia.edu.
4
Department of Emergency Medicine, University of California, Davis, CA. Electronic address: daniel.nishijima@ucdmc.ucdavis.edu.

Abstract

OBJECTIVE:

The antifibrinolytic agent tranexamic acid (TXA) has demonstrated clinical benefit in trauma patients with severe bleeding, but its effectiveness in patients with traumatic brain injury (TBI) is unclear. We conducted a systematic review to evaluate the following research question: In ED patients with or at risk of intracranial hemorrhage (ICH) secondary to TBI, does TXA compared to placebo improve patients' outcomes?

METHODS:

MEDLINE, EMBASE, CINAHL, and other databases were searched for randomized controlled trial (RCT) or quasi-RCT studies that compared the effect of TXA to placebo on outcomes of TBI patients. The main outcomes of interest included mortality, neurologic function, hematoma expansion, and adverse effects. We used "Grading quality of evidence and strength of recommendations" to assess the quality of trials. Two authors independently abstracted data using a data collection form. Results from studies were pooled when appropriate.

RESULTS:

Of 1030 references identified through the search, 2 high-quality RCTs met inclusion criteria. The effect of TXA on mortality had a pooled relative risk of 0.64 (95% confidence interval [CI], 0.41-1.02); on unfavorable functional status, a relative risk of 0.77 (95% CI, 0.59-1.02); and on ICH progression, a relative risk of 0.76 (95% CI, 0.58-0.98). No serious adverse effects (such as thromboembolic events) associated with TXA group were reported in the included trials.

CONCLUSION:

Pooled results from the 2 RCTs demonstrated statistically significant reduction in ICH progression with TXA and a nonstatistically significant improvement of clinical outcomes in ED patients with TBI. Further evidence is required to support its routine use in patients with TBI.

PMID:
25447601
PMCID:
PMC4988127
DOI:
10.1016/j.ajem.2014.09.023
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center